Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Irinotecan and 5-FU/FA in Metastatic Gastric Cancer
NCT01123811Phase 2Completed
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- May 2006
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in gastric adenocarcinoma and esophagogastric junction adenocarcinoma (GEJA), sponsored by Johannes Gutenberg University Mainz. Primary endpoint: Objective Response Rate at 1 month. Started May 2006; status: completed.
02
Drugs
KL-140
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT01123811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01123811.